Clinical Trial Update: Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sintilimab and nimotuzumab in combination with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Nimotuzumab (nimotuzumab)
• Sintilimab (sintilimab)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN